Opinion|Videos|May 28, 2024
Choosing Between Medical and Surgical Options for Hypercortisolism
Medical professionals discuss their ideal patients for surgery, and who would be best suited for pharmacologic intervention.
Advertisement
Episodes in this series
Advertisement
Related to this article
Catch up on key FDA approvals, major trial updates, and critical clinician insights from the last 3 months.
EloraTZP cut body weight by up to 23.3% and A1C by up to 2.9% at 48 weeks vs 14.8% and 2.4% with tirzepatide 15 mg in a phase 2b trial.
Advertisement
Advertisement
Trending on HCPLive
1
Ritlecitinib Stabilizes Vitiligo in Tranquillo Trial, With Iltefat Hamzavi, MD
2
Advances in Treating High-Impact Psoriasis from EADV 2026
3
FDA Updates Sotatercept Label, ERS Releases PAH Guidelines to Include HYPERION Data
4
From Injectable to Oral: Optimal Durable Clearance Across the IL-23 Class
5